Introduction: This study investigated the clinical efficacy and safety of photoselective vaporization of the prostate (PVP) and simultaneous suprapubic cystostomy for benign prostatic hyperplasia (BPH) in patients with mild to severe detrusor underactivity (DU). Subjects and Methods: Seventy-eight patients with BPH were divided into 3 groups according to the severity of DU: mild DU group, moderate DU group and severe DU group. The preoperative and postoperative data, including the detrusor pressure at maximum flow (Pdetmax), bladder compliance, maximum urinary flow (Qmax), postvoid residual urine (PVR) values, International Prostate Symptom Score (IPSS) and quality of life (QoL) were evaluated. Results: The therapeutic effectiveness including cure and improvement in mild and moderate DU group was significantly higher than that of the severe group. Compared to the preoperative values, Pdetmax, bladder compliance, Qmax, PVR, IPSS and QoL scores at 12 months postoperatively had significantly improved. In addition, the above parameters at 12 months postoperatively in the mild or moderate DU group had significant difference compared to the severe DU group. Conclusion: PVP and simultaneous suprapubic cystostomy seem to be an appropriate treatment modality in BPH patients with mild and/or moderate DU as well as in patients with severe DU and slightly reduced bladder compliance.

Keywords:
Benign prostatic hyperplasia, Cystostomy, Detrusor underactivity, Photoselective vaporization of the prostate
1.
Cabelin MA, Te AE, Kaplan SA: Benign prostatic hyperplasia: Challenges for the new millennium. Curr Opin Urol 2000;10:301-306.
2.
Roehrborn C, McConnell J: Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia; in Walsh P, Retik A, Vaughan EJ, Wein A (eds): Campbell's Urology. Philadelphia, WB Saunders Company, 2002, pp 1297-1330.
3.
Beckman TJ, Mynderse LA: Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 2005;80:1356-1362.
4.
Skillinge D, Langan R, Krafczyk M, McGarey M: Benign prostate hyperplasia: a clinical review. Osteopath Fam Phys 2011;3:182-186.
5.
Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X: Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014;93:214-219.
6.
Pan JG, Jiang C, Luo R, Zhou X: Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urol Int 2014;93:10-16.
7.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002;21:167-178.
8.
Paick JS, Um JM, Kwak C, Kim SW, Ku JH: Influence of bladder contractility on short-term outcomes of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate. Urology 2007;69:859-863.
9.
Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P: The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004;93:745-750.
10.
Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T: The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int 2010;105:1429-1433.
11.
AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-547.
12.
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ: EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-554.
13.
Seki N, Yuki K, Takei M, Yamaguchi A, Naito S: Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. Neurourol Urodyn 2009;28:197-201.
14.
Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S: Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology 2007;70:1096-1099.
15.
Monoski MA, Gonzalez RR, Sandhu JS, Reddy B, Te AE: Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. Urology 2006;68:312-317.
16.
Van Venrooij GE, Eckhardt MD, Boon TA: Data from frequency-volume charts versus maximum free flow rate, residual volume, and voiding cystometric estimated urethral obstruction grade and detrusor contractility grade in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourol Urodyn 2002;21:450-456.
17.
Bouchier-Hayes DM, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello AJ: A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int 2010;105:964-969.
18.
Lee R, Gonzalez RR, Te AE: The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia. World J Urol 2006;24:405-409.
19.
Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T: High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005;173:158-160.
20.
Barber NJ, Zhu G, Donohue JF, Thompson PM, Walsh K, Muir GH: Use of expired breath ethanol measurements in evaluation of irrigant absorption during high-power potassium titanyl phosphate laser vaporization of prostate. Urology 2006;67:80-83.
21.
Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, Malek RS: Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 2004;172:1404-1408.
22.
Rieken M, Bachmann A: Update on greenlight laser vaporization (PVP) 2014. World J Urol 2015;33:531-537.
23.
Bachmann A, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, Grimm MO, Benejam J, Stolzenburg JU, Riddick A, Pahernik S, Roelink H, Ameye F, Saussine C, Bruyère F, Loidl W, Larner T, Gogoi NK, Hindley R, Muschter R, Thorpe A, Shrotri N, Graham S, Hamann M, Miller K, Schostak M, Capitán C, Knispel H, Thomas JA: 180-W XPS greenlight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial - the GOLIATH study. Eur Urol 2014;65:931-942.
24.
Suskind AM, Smith PP: A new look at detrusor underactivity: impaired contractility versus afferent dysfunction. Curr Urol Rep 2009;10:347-351.
25.
Van Koeveringe GA, Rademakers KL: Factors impacting bladder underactivity and clinical implications. Minerva Urol Nefrol 2015;67:139-148.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.